| 1 | HARTWELL, Leland H., et al. Integrating genetic approaches into the discovely of anticancer drugs. Science, 1997, 278.5340: 1064-1068 DOI |
| 2 | PAO, William, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine, 2005, 2. 1: e17 DOI ScienceOn |
| 3 | GRANT, Richard W., et al. Personalized genetic risk counseling to motivate diabetes prevention a randomized trial. Diabetes care, 2013, 36.1: 13-19. DOI |
| 4 | GOLUB, Todd R., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. science, 1999, 286.5439: 531-537. DOI ScienceOn |
| 5 | SOLIT, David B., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature, 2005, 439.7074: 358-362. |
| 6 | SHOEMAKER, Robert H. The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer, 2006, 6.10: 813-823. DOI |
| 7 | SOS, Martin L., et al. Predicting drug susceptibility of non - small cell lung cancers based on genetic lesions. The Journal of clinical investigation, 2009, 119.6: 1727-1740. DOI |
| 8 | STAUNTON, Jane E., et al. Chemosensitivity prediction by transcriptional profiling. Proceedings of the National Academy of Sciences, 2001 , 98.19: 10787-10792. DOI ScienceOn |
| 9 | TAN, Aik Choon; GILBERT, David. Ensemble machine leaming on gene expression data for cancer classification. 2003. |
| 10 | CROCE, Carlo M. Oncogenes and cancer. New England Journal of Medicine, 2008, 358.5: 502-511. DOI ScienceOn |
| 11 | WAGLE, Nikhil, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology, 2011, 29.22: 3085-3096. DOI |
| 12 | DRY, Jonathan R., et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer research, 2010, 70.6: 2264-2273. DOI |
| 13 | PAIK, Soonmyung, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine, 2004, 351.27: 2817-2826. DOI ScienceOn |
| 14 | MA, Xiao-Jun, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Archives of pathology & laboratory medicine, 2006, 130.4: 465-473 |
| 15 | LEE, Jae K., et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proceedings of the National Academy of Sciences, 2007, 104.32: 13086-13091. DOI ScienceOn |
| 16 | SOUKUP, Mat; CHO, Hyungjun; LEE, Jae K. Robust classification modeling on microarray data using misclassification penalized posterior. Bioinformatics, 2005, 21.suppl 1: i423-i430. DOI ScienceOn |
| 17 | BERLOW, Noah, et al. A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. BMC bioinformatics, 2013, 14. 1: 239. DOI |
| 18 | PAL, Ranadip; BERLOW, Noah. Akinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs. In: Pacific Symposium on Biocomputing. 2012. p. 351-62 |
| 19 | KUMAR, Rahul, et al. CancerDR: cancer drug resistance database. Scientific reports, 2013, 3. |
| 20 | BARRETINA, Jordi, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 2012, 483.7391: 603-607. DOI ScienceOn |
| 21 | GRESHOCK, Joel, et al. Molecular target class is predictive of in vitro response profile. Cancer research, 2010, 70.9: 3677-3686. DOI |
| 22 | YANG, Wanjuan, et al. Genornics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic acids research, 2013, 41.D1: D955-D961. DOI |
 |
Korea Institute of Science and Technology Information
Gwahangno, Yuseong-gu, Daejeon, 305-806, Korea TEL : +82-42-869-1752
Copyright (c) 2009 KISTI. All Rights Reserved. For more information mail to
webmaster
